MitoRx Therapeutics Logo
Our Science
Pipeline
Our Team
SAB
News
Contact
HomeOur SciencePipelineOur TeamNewsContact

MitoRx

Clinical and Scientific
Advisory Board

MitoRx's Clinical and Scientific Advisory Board (SAB) is being developed for scientific review of our R&D activities and to help senior management make the best scientific and clinical development decisions.

Our team ↗

Members

Chair of the Scientific Advisory Board

Prof Chas Bountra OBE

Chas is Pro-Vice Chancellor for Innovation at the University of Oxford, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine, Director of the Centre for Medicines Discovery, and Professorial Fellow at Keble College, Oxford. Prior to returning to Oxford in 2008, Chas was Vice President and Head of Biology at GlaxoSmithKline.

Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes. In 2012 he was voted one of the “top innovators in the industry”, in 2014 received the “Rita and John Cornforth Award” from the Royal Society of Chemistry, in 2017 and 2018 was voted “Master of the Bench” from the Medicine Maker Power List, and in 2018 was awarded the “Order of the British Empire” in the New Years Honours List.

Scientific Advisory Board MembEr

Prof Rury Holman MB, ChB. FRCP(Lon). FMedSci

Rury is a globally recognized authority on diabetes and cardiometabolic diseases. He is an Emeritus Professor of Diabetic Medicine at the University of Oxford and former Director of the University of Oxford Diabetes Trials Unit, where he has led groundbreaking clinical research in diabetes management and cardiometabolic diseases.

His accolades, including the ADA Harold Rifkin Award for Distinguished International Service, the Diabetes UK Robert Turner Award for Research Impact and the 2024 ADA Banting Medal for Scientific Achievement, underscore his significant contributions to the field. Rury’s scientific insight will be instrumental as MitoRx pioneers new approaches targeting mitochondria in obesity, aiming to develop innovative therapies that address the underlying mechanisms of metabolic disease.

Scientific Advisory Board Member

Prof Dame Kay Davies CBE DBE FRS FMedSci

Kay is Dr Lee’s Professor of Anatomy Emeritus the University of Oxford Oxford with an international reputation for work on Duchenne muscular dystrophy paving the way for several nucleic acid related therapies. Prof Davies is a co-founder and co-Director of the MDUK Oxford Neuromuscular Centre, and co-founded Summit Therapeutics plc which translated her work on DMD into late-stage clinical trials.

Scientific Advisory Board Member

Prof Laurent Servais MD PhD

Laurent directs the Specialised Translational Research Oxford Neuromuscular Group as Professor of Paediatric Neuromuscular Disease at the University of Oxford, and he is Professor of Child Neurology at the University of Liège. He brings a wealth of experience to the Scientific Advisory Board having led many clinical trials as principal investigator for Duchenne muscular dystrophy and spinal muscular atrophy treatments.

Scientific Advisory Board Member

Dr Bernd C Schwahn MD PhD FRCPCH

Bernd is Consultant in Paediatric Metabolic Medicine at the Manchester University NHS Foundation Trust and Honorary Clinical Senior Lecturer in Genomic Medicine, also joins the board. Dr Schwahn’s scientific interest focuses on disorders of sulfur amino acid metabolism and has been involved as principal and chief investigator in clinical trials for the treatment of molybdenum cofactor deficiency, lysosomal storage disorders and disorders of intermediary metabolism.

Scientific Advisory Board Member

Dr. Caroline Le Guiner

Dr. Caroline Le Guiner is a renowned preclinical expert and team leader at the TaRGeT lab (Translational Research for Gene Therapy, INSERM, Nantes Université and University Hospital of Nantes) in Nantes, France, who  has over two decades of experience in translational research focused on gene therapy for rare muscular diseases, playing a pivotal role in coordinating international networks aimed at developing therapeutic solutions for Duchenne Muscular Dystrophy (DMD).

Scientific Advisory Board Member

Dr. Milos Filipovic

Dr. Milos Filipovic is a distinguished researcher with expertise in chemical biology who brings his wealth of experience in cysteine post-translational modifications and their implications in aging and aging-associated diseases. Having led research groups at prestigious institutions such as the French National Centre for Scientific Research (CNRS) and the Leibniz Institute for Analytical Sciences in Dortmund, Dr. Filipovic's insights will be invaluable in advancing MitoRx's understanding of redox changes in cellular signaling.

Scientific Advisory Board Member

Professor Phil Hansbro

Professor Phil Hansbro is a globally recognized authority in respiratory research. As Director of the Centenary/UTS Centre for Inflammation, he has made significant contributions to the identification of novel treatments for chronic lung diseases. His extensive publication record and track record in securing research funding underscore his expertise in this field. He led the presentation of research at the 10th Annual Meeting of the International Cytokine and Interferon Society which showed MitoRx’s compounds provided an anti-fibrotic effect and preserved lung function in a COPD model.

Scientific Advisory Board Member

Professor Annemieke Aartsma-Rus

Professor Annemieke Aartsma-Rus is professor of translational genetics at the Leiden University Medical Center (LUMC). She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University. Since 2016 until now she was elected as the most influential scientist in the field of Duchenne muscular dystrophy based on publications of the past decade. In 2014 she was accepted in the Jonge Akademie (Dutch Royal Academy of Sciences), consisting of the 50 most prominent scientists of under 45.

MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director.

Read Press Release↗
MitoRx Therapeutics Logo

Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration.

Mail Icon

info@mitorxtherapeutics.com

Phone Icon

+44 1235 838631

Follow Us
About Us
HomeOur scienceOur teamContactNews
Legal
Privacy policyTerms of use
© Copyright 2021 MitoRx Therapeutics Limited - All Rights Reserved
9400 Garsington Road, Oxford Business Park Oxford OX4 2HN
Registered in England and Wales Company No. 13237941
Website by Stefan Benfield